Please wait while the formulary information is being retrieved.
NIACIN INOSITOL (NIACIN (INOSITOL NIACINATE))
- Niacin deficiency
- Pellagra
Niacin No Flush 400 mg niacin (500 mg) capsule
- Dosage information is not available
400 mg niacin (500 mg) capsule
- Dosage information is not available
750 mg capsule
- Dosage information is not available
Flush Free 400 mg (500 mg) capsule
- Dosage information is not available
Flush Free 750 mg capsule
- Dosage information is not available
Niacin Flush Free 400 mg niacin (500 mg) capsule
- Dosage information is not available
Niacin Flush Free 750 mg capsule
- Dosage information is not available
niacin (inositol niacinate) 500 mg capsule
- Dosage information is not available
niacin (inositol niacinate) 750 mg capsule
- Dosage information is not available
niacin 400 mg (inositol niacinate 500 mg) capsule
- Dosage information is not available
niacin 455 mg (inositol niacinate 500 mg) capsule
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Acute cerebral infarction
- Acute myocardial infarction
- Arterial hemorrhage
- Cerebrovascular accident
- Disease of liver
- Peptic ulcer
Contraindicated
- Abnormal hepatic function tests
- Alcoholism
Severe
Moderate
- 30 day risk period post-myocardial infarction
- Cerebrovascular insufficiency
- Diabetes mellitus
- Gout
- Hypophosphatemia
- Hypotension
- Increased risk of bleeding due to coagulation disorder
NIACIN INOSITOL (NIACIN (INOSITOL NIACINATE))
- Niacin deficiency
- Pellagra
- None
- None
More Frequent
Severe
Less Severe
- None
- Cardiac arrhythmia
- Diarrhea
- Dizziness
- Dry eye
- Dry skin
- Exacerbation of peptic ulcer
- Flushing
- Headache disorder
- Hyperglycemia
- Hyperuricemia
- Myalgias
- Nausea
- Pruritus of skin
- Syncope
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Niacin (> 50 Mg)
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Niacin
Potential adverse effect on infant with lipid altering dose
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Potential adverse effect on infant with lipid altering dose |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Niacin deficiency | |
| E52 | Niacin deficiency [pellagra] |
| Pellagra | |
| E52 | Niacin deficiency [pellagra] |
| 0-9 | A-Z |
|---|---|
| E52 | Niacin deficiency [pellagra] |
| E52 | Niacin deficiency [pellagra] |
Formulary Reference Tool